CERENOVUS, Inc., part of Johnson & Johnson MedTech*, today announced positive primary outcomes from the real-world EXCELLENT Registry focused on stroke-inducing blood clot removal by mechanical thrombectomy at the Society of Vascular and Interventional Neurology (SVIN) annual meeting, taking place in Los Angeles, CA from November 16-19, 2022.
| EXCELLENT study demonstrates real-world benefits of CERENOVUS’ EMBOTRAP™ Revascularization Devices on clinical outcomes and first pass reperfusion IRVINE, Calif., Nov. 18, 2022 /PRNewswire/ -- CERENOVUS, Inc., part of Johnson & Johnson MedTech*, today announced positive primary outcomes from the real-world EXCELLENT Registry focused on stroke-inducing blood clot removal by mechanical thrombectomy at the Society of Vascular and Interventional Neurology (SVIN) annual meeting, taking place in Los Angeles, CA from November 16-19, 2022.1
Stroke is the second-leading cause of death worldwide,i with ischemic stroke being the most common type.ii Launched by CERENOVUS in 2018, the EXCELLENT Registry is the largest global acute ischemic stroke registry, which collects patient data, imaging and clots on a per pass basis and leverages independent adjudication by an imaging core lab and clinical events committee. All patients enrolled in the registry were treated with CERENOVUS EMBOTRAP™ II or EMBOTRAP™ III Revascularization Devices as a first line therapy. Offered within the CERENOVUS ischemic portfolio, the EMBOTRAP™ family of devices are next generation stent retrievers designed to remove clots during mechanical thrombectomy procedures. Stent retrievers help achieve first pass recanalization, which is associated with the greatest patient benefits.iii The EXCELLENT registry aims to advance stroke care by characterizing the EMBOTRAP™ device at multiple hospitals using the technique of choice to reflect current practice patterns, and evaluating the clots retrieved to identify the potential impact different clot compositions can have on patient outcomes. The EXCELLENT data released today comprises 1,000 ischemic stroke patients from 36 sites worldwide. Primary results collected from 2018 to present include:
“The positive preliminary findings of this research provide real-world results that demonstrate advances are possible in mechanical thrombectomy procedures to treat ischemic stroke,” said Mark Dickinson, Worldwide President of CERENOVUS. “It is encouraging to see these positive results and realize the impact this data can have on improved patient outcomes and changing the trajectory of stroke.” The EXCELLENT Registry is a large international multicenter cohort of “all-comers,” featuring a wide range of stroke cases, including patients who in the past have not been considered good thrombectomy candidates. The clots will be analyzed by blinded central labs under standard protocol, which furthers prior stroke science research conducted by CERENOVUS’ Neuro Thromboembolic Initiative (NTI). To build on its important discoveries, the EXCELLENT Registry is being expanded to 1,000 additional stroke patients and will include new sites in China and Japan; the expanded study will also include CERENOVUS Large Bore Catheter™/EMBOVAC™ to examine the impact of direct aspiration as a first line treatment and enable researchers to study clots retrieved through both direction aspiration and stent retrievers. For more information on CERENOVUS’ portfolio, visit https://www.jnjmedtech.com/en-US/company/cerenovus/products. About CERENOVUS About Johnson & Johnson MedTech Cautions Concerning Forward-Looking Statements * Johnson & Johnson MedTech comprises the surgery, orthopaedics, vision and interventional solutions businesses. CERENOVUS is part of Johnson & Johnson MedTech. Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, side effects, warnings and precautions. 230872-221025 1 Results were presented for the first time at the World Stroke Congress in Singapore in October 2022. i “The Top 10 Causes of Death.” World Health Organization. 2020. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death#:~:text=Stroke%20and%20chronic%20obstructive%20pulmonary,4th%20leading%20cause%20of%20death. Media Contact:
SOURCE CERENOVUS |
View original content to download multimedia:
